{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:11:14Z","timestamp":1791205874257,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"23","license":[{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,12,1]],"date-time":"2012-12-01T00:00:00Z","timestamp":1354320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,12,11]],"date-time":"2013-12-11T00:00:00Z","timestamp":1386720000000},"content-version":"vor","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American College of Cardiology"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1016\/j.jacc.2012.04.064","type":"journal-article","created":{"date-parts":[[2012,11,7]],"date-time":"2012-11-07T15:45:35Z","timestamp":1352303135000},"page":"2349-2356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?"],"prefix":"10.1016","volume":"60","author":[{"given":"Ross T.","family":"Campbell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Castagno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel M.","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark C.","family":"Petrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.V.","family":"McMurray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2012.04.064_bib1","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jacc.2009.06.067","article-title":"Treatment of heart failure with normal ejection fraction: an inconvenient truth!","volume":"55","author":"Paulus","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jacc.2008.12.007","article-title":"Heart failure with normal left ventricular ejection fraction","volume":"53","author":"Maeder","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib3","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib4","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1056\/NEJMoa051530","article-title":"Outcome of heart failure with preserved ejection fraction in a population-based study","volume":"355","author":"Bhatia","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.jacc.2003.07.046","article-title":"Heart failure with preserved left ventricular systolic function; epidemiology, clinical characteristics, and prognosis","volume":"43","author":"Hogg","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib6","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/eurheartj\/ehm554","article-title":"Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study","volume":"29","author":"Tribouilloy","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2012.04.064_bib7","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1093\/eurjhf\/hfq121","article-title":"Epidemiology and clinical course of heart failure with preserved ejection fraction","volume":"13","author":"Lam","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2012.04.064_bib8","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.jacc.2005.09.022","article-title":"Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database","volume":"47","author":"Yancy","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib9","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2007.04.064","article-title":"Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry","volume":"50","author":"Fonarow","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.ehj.2004.06.006","article-title":"Differences between patients with a preserved and a depressed left ventricular function: a report from the EuroHeart Failure Survey","volume":"25","author":"Lenzen","year":"2004","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2012.04.064_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijcard.2010.04.025","article-title":"HFNEF breathlessness: is it really heart failure?","volume":"143","author":"Henein","year":"2010","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bmj.321.7255.215","article-title":"Do patients with suspected heart failure and preserved left ventricular systolic function suffer from \u201cdiastolic heart failure\u201d or from misdiagnosis?","volume":"321","author":"Caruana","year":"2000","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2012.04.064_bib13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1136\/hrt.2007.131144","article-title":"Perception of symptoms is out of proportion to cardiac pathology in patients with \u201cdiastolic heart failure.\u201d","volume":"94","author":"Ingle","year":"2008","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2012.04.064_bib14","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1161\/CIRCHEARTFAILURE.111.963710","article-title":"Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction?","volume":"4","author":"Packer","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2012.04.064_bib15","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/eurjhf\/hfp103","article-title":"The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis","volume":"11","author":"Somaratne","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2012.04.064_bib16","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/eurheartj\/ehr254","article-title":"The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis","volume":"33","year":"2012","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2012.04.064_bib17","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1161\/CIRCULATIONAHA.106.628347","article-title":"Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial","volume":"114","author":"Ahmed","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.04.064_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib19","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","article-title":"Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial","volume":"362","author":"Yusuf","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.04.064_bib20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.04.064_bib21","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.04.064_bib22","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ejheart.2007.12.010","article-title":"Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial","volume":"10","author":"McMurray","year":"2008","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.jacc.2012.04.064_bib23","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","article-title":"Irbesartan in patients with heart failure and preserved ejection fraction","volume":"359","author":"Massie","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib24","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(04)16980-8","article-title":"Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial","volume":"364","author":"Poole-Wilson","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.04.064_bib25","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa0802743","article-title":"Effects of intensive glucose lowering in type 2 diabetes","volume":"358","author":"Gerstein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib26","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","article-title":"Major Outcomes in High-Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)","volume":"288","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2012.04.064_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMoa021716","article-title":"A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly","volume":"348","author":"Wing","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","article-title":"Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol","volume":"359","author":"Dahl\u00f6f","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.04.064_bib29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/01.HYP.32.6.989","article-title":"Characteristics of 9194 patients with left ventricular hypertrophy: the LIFE study","volume":"32","author":"Dahl\u00f6f","year":"1998","journal-title":"Hypertension"},{"key":"10.1016\/j.jacc.2012.04.064_bib30","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/08037050903047202","article-title":"Pulse pressure, left ventricular function and cardiovascular events during antihypertensive treatment (the LIFE study)","volume":"18","author":"Gerdts","year":"2009","journal-title":"Blood Press"},{"key":"10.1016\/j.jacc.2012.04.064_bib31","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","article-title":"Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomized trial","volume":"363","author":"Julius","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.04.064_bib32","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1056\/NEJMoa0801369","article-title":"Treatment of hypertension in patients 80 years of age or older","volume":"358","author":"Beckett","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib33","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/S0140-6736(99)10327-1","article-title":"Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study","volume":"354","author":"Hansson","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2012.04.064_bib34","doi-asserted-by":"crossref","first-page":"631","DOI":"10.7326\/0003-4819-137-8-200210150-00006","article-title":"Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function","volume":"137","author":"Gottdiener","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib35","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1016\/j.amjcard.2011.01.051","article-title":"Comparison of characteristics and outcomes of asymptomatic versus symptomatic left ventricular dysfunction in subjects 65 years old or older (from the Cardiovascular Health Study)","volume":"107","author":"Pandhi","year":"2011","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijcard.2010.10.007","article-title":"Differential impact of heart rate and blood pressure on outcome in patients with heart failure with reduced versus preserved left ventricular ejection fraction","volume":"155","author":"Maeder","year":"2012","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib37","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1161\/01.CIR.0000144474.65922.AA","article-title":"Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program","volume":"110","author":"Solomon","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.04.064_bib38","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1161\/CIRCULATIONAHA.109.909614","article-title":"Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial","volume":"121","author":"Zile","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.04.064_bib39","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1056\/NEJMoa1008816","article-title":"Irbesartan in patients with atrial fibrillation","volume":"364","author":"Yusuf","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2012.04.064_bib40","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1080\/08037050152112050","article-title":"Echocardiographic left ventricular geometry in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study","volume":"10","author":"Devereux","year":"2001","journal-title":"Blood Press"},{"key":"10.1016\/j.jacc.2012.04.064_bib41","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1161\/CIRCULATIONAHA.110.011031","article-title":"Prevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fraction","volume":"124","author":"Zile","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2012.04.064_bib42","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.jacc.2006.08.062","article-title":"Diastolic dysfunction in heart failure with preserved systolic function: need for objective evidence: results from the CHARM Echocardiographic Substudy-CHARMES","volume":"49","author":"Persson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2012.04.064_bib43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.cardfail.2009.09.007","article-title":"Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial","volume":"16","author":"McKelvie","year":"2010","journal-title":"J Card Fail"},{"key":"10.1016\/j.jacc.2012.04.064_bib44","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1097\/01.hjh.0000239288.10013.04","article-title":"N-terminal brain natriuretic peptide predicted cardiovascular events stronger than high-sensitivity C-reactive protein in hypertension: a LIFE substudy","volume":"24","author":"Olsen","year":"2006","journal-title":"J Hypertens"},{"key":"10.1016\/j.jacc.2012.04.064_bib45","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCHEARTFAILURE.109.932996","article-title":"Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE)","volume":"4","author":"Komajda","year":"2011","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.jacc.2012.04.064_bib46","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/hrt.2010.205815","article-title":"Resting global and regional left ventricular contractility in patients with heart failure and normal ejection fraction: insights from speckle-tracking echocardiography","volume":"97","author":"Yip","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.jacc.2012.04.064_bib47","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/eurjhf\/hfs049","article-title":"Relationship between plasma concentrations of N-terminal pro brain natriuretic peptide and the characteristics and outcome of patients with a clinical diagnosis of diastolic heart failure: a report from the PEP-CHF study","volume":"14","author":"Cleland","year":"2012","journal-title":"Eur J Heart Fail"}],"container-title":["Journal of the American College of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712046402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109712046402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:54:39Z","timestamp":1760014479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109712046402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":47,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["S0735109712046402"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2012.04.064","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"What Have We Learned About Patients With Heart Failure and Preserved Ejection Fraction From DIG-PEF, CHARM-Preserved, and I-PRESERVE?","name":"articletitle","label":"Article Title"},{"value":"Journal of the American College of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2012.04.064","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}